Literature DB >> 19319660

Changes in gait pattern as assessed by the GAITRite™ walkway system in MPS II patients undergoing enzyme replacement therapy.

M Wood1, M A Cleary, L Alderson, A Vellodi.   

Abstract

Patients with MPS II often present with limitations to functional mobility. With the advent of enzyme replacement therapy (ERT), robust assessment tools are important to assess response to treatment. The aim of this study was to see if the GAITRite™ system (electronic pressure sensitive walkway) could identify any changes to gait pattern following commencement of ERT. Six boys with MPS type II were assessed at baseline and at intervals post commencing ERT. Four individual characteristics of gait were studied - velocity, cadence, step length and base of support. Changes in parameters for each individual could be analysed and be compared with age matched controls. The data generated from the GAITRite™ indicated all six boys had changes to their gait pattern. The most notable changes were in velocity, step length and base of support. The GAITRite™ was found to identify changes in gait parameters in this group of patients. It is an accessible way of providing both quantitative and qualitative analysis of gait in the clinical environment, and could potentially be used to monitor response to treatment. Larger studies are needed to corroborate our findings, as well as to establish the GAITRite™ as a monitoring tool.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19319660     DOI: 10.1007/s10545-009-1103-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Concurrent related validity of the GAITRite walkway system for quantification of the spatial and temporal parameters of gait.

Authors:  Belinda Bilney; Meg Morris; Kate Webster
Journal:  Gait Posture       Date:  2003-02       Impact factor: 2.840

2.  Reliability of the GAITRite walkway system for the quantification of temporo-spatial parameters of gait in young and older people.

Authors:  Vinay Parmar; A J Shyam Kumar; W M Harper
Journal:  Gait Posture       Date:  2005-07-07       Impact factor: 2.840

3.  British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood.

Authors:  T J Cole; J V Freeman; M A Preece
Journal:  Stat Med       Date:  1998-02-28       Impact factor: 2.373

4.  A physical performance measure for individuals with mucopolysaccharidosis type I.

Authors:  Stephen M Haley; Maria A Fragala Pinkham; Helene M Dumas; Pengsheng Ni; Alison M Skrinar; Gerald F Cox
Journal:  Dev Med Child Neurol       Date:  2006-07       Impact factor: 5.449

5.  A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

Authors:  Joseph Muenzer; Muge Gucsavas-Calikoglu; Shawn E McCandless; Thomas J Schuetz; Alan Kimura
Journal:  Mol Genet Metab       Date:  2006-12-20       Impact factor: 4.797

6.  Gait parameters in children with motor disabilities using an electronic walkway system: assessment of reliability.

Authors:  Valerie C Wondra; Kenneth H Pitetti; Michael W Beets
Journal:  Pediatr Phys Ther       Date:  2007       Impact factor: 3.049

Review 7.  Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.

Authors:  J Edmond Wraith
Journal:  Acta Paediatr       Date:  2008-04       Impact factor: 2.299

8.  Can early subclinical gait changes in children with haemophilia be identified using the GAITRite walkway.

Authors:  M Bladen; L Alderson; K Khair; R Liesner; J Green; E Main
Journal:  Haemophilia       Date:  2007-09       Impact factor: 4.287

Review 9.  Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).

Authors:  Rick Martin; Michael Beck; Christine Eng; Roberto Giugliani; Paul Harmatz; Verónica Muñoz; Joseph Muenzer
Journal:  Pediatrics       Date:  2008-02       Impact factor: 7.124

10.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

View more
  3 in total

1.  Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points.

Authors:  Emma Glamuzina; Emma Fettes; Katie Bainbridge; Victoria Crook; Niamh Finnegan; Lara Abulhoul; Ashok Vellodi
Journal:  J Inherit Metab Dis       Date:  2011-02-16       Impact factor: 4.982

Review 2.  The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

Authors:  Robin Lachmann; Benedikt Schoser
Journal:  Orphanet J Rare Dis       Date:  2013-10-12       Impact factor: 4.123

3.  Comparison between a center of mass and a foot pressure sensor system for measuring gait parameters in healthy adults.

Authors:  Gunoh Park; Youngkeun Woo
Journal:  J Phys Ther Sci       Date:  2015-10-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.